Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
05 2022
Historique:
received: 21 12 2021
revised: 17 01 2022
accepted: 19 01 2022
pubmed: 22 2 2022
medline: 20 4 2022
entrez: 21 2 2022
Statut: ppublish

Résumé

South Africa reported a notable increase in COVID-19 cases from mid-November, 2021, onwards, starting in Tshwane District, which coincided with the rapid community spread of the SARS-CoV-2 omicron (B.1.1.529) variant. This increased infection rate coincided with a rapid increase in paediatric COVID-19-associated admissions to hospital (hereafter referred to as hospitalisations). The Tshwane Maternal-Child COVID-19 study is a multicentre observational study in which we investigated the clinical manifestations and outcomes of paediatric patients (aged ≤19 years) who had tested positive for SARS-CoV-2 and were admitted to hospital for any reason in Tshwane District during a 6-week period at the beginning of the fourth wave of the COVID-19 epidemic in South Africa. We used five data sources, which were: (1) COVID-19 line lists; (2) collated SARS-CoV-2 testing data; (3) SARS-CoV-2 genomic sequencing data; (4) COVID-19 hospitalisation surveillance; and (5) clinical data of public sector COVID-19-associated hospitalisations among children aged 13 years and younger. Between Oct 31 and Dec 11, 2021, 6287 children and adolescents in Tshwane District were recorded as having COVID-19. During this period, 2550 people with COVID-19 were hospitalised, of whom 462 (18%) were aged 19 years or younger. The number of paediatric cases was higher than in the three previous SARS-CoV-2 waves, uncharacteristically increasing ahead of adult hospitalisations. 75 viral samples from adults and children in the district were sequenced, of which 74 (99%) were of the omicron variant. Detailed clinical notes were available for 138 (75%) of 183 children aged ≤13 years with COVID-19 who were hospitalised. 87 (63%) of 138 children were aged 0-4 years. In 61 (44%) of 138 cases COVID-19 was the primary diagnosis, among whom symptoms included fever (37 [61%] of 61), cough (35 [57%]), shortness of breath (19 [31%]), seizures (19 [31%]), vomiting (16 [26%]), and diarrhoea (15 [25%]). Median length of hospital stay was 2 days [IQR 1-3]). 122 (88%) of 138 children with available data needed standard ward care and 27 (20%) needed oxygen therapy. Seven (5%) of 138 children were ventilated and four (3%) died during the study period, all related to complex underlying copathologies. All children and 77 (92%) of 84 parents or guardians with available data were unvaccinated to COVID-19. Rapid increases in paediatric COVID-19 cases and hospitalisations mirror high community transmission of the SARS-CoV-2 omicron variant in Tshwane District, South Africa. Continued monitoring is needed to understand the long-term effect of the omicron variant on children and adolescents. South African Medical Research Council, South African Department of Science & Innovation, G7 Global Health Fund.

Sections du résumé

BACKGROUND
South Africa reported a notable increase in COVID-19 cases from mid-November, 2021, onwards, starting in Tshwane District, which coincided with the rapid community spread of the SARS-CoV-2 omicron (B.1.1.529) variant. This increased infection rate coincided with a rapid increase in paediatric COVID-19-associated admissions to hospital (hereafter referred to as hospitalisations).
METHODS
The Tshwane Maternal-Child COVID-19 study is a multicentre observational study in which we investigated the clinical manifestations and outcomes of paediatric patients (aged ≤19 years) who had tested positive for SARS-CoV-2 and were admitted to hospital for any reason in Tshwane District during a 6-week period at the beginning of the fourth wave of the COVID-19 epidemic in South Africa. We used five data sources, which were: (1) COVID-19 line lists; (2) collated SARS-CoV-2 testing data; (3) SARS-CoV-2 genomic sequencing data; (4) COVID-19 hospitalisation surveillance; and (5) clinical data of public sector COVID-19-associated hospitalisations among children aged 13 years and younger.
FINDINGS
Between Oct 31 and Dec 11, 2021, 6287 children and adolescents in Tshwane District were recorded as having COVID-19. During this period, 2550 people with COVID-19 were hospitalised, of whom 462 (18%) were aged 19 years or younger. The number of paediatric cases was higher than in the three previous SARS-CoV-2 waves, uncharacteristically increasing ahead of adult hospitalisations. 75 viral samples from adults and children in the district were sequenced, of which 74 (99%) were of the omicron variant. Detailed clinical notes were available for 138 (75%) of 183 children aged ≤13 years with COVID-19 who were hospitalised. 87 (63%) of 138 children were aged 0-4 years. In 61 (44%) of 138 cases COVID-19 was the primary diagnosis, among whom symptoms included fever (37 [61%] of 61), cough (35 [57%]), shortness of breath (19 [31%]), seizures (19 [31%]), vomiting (16 [26%]), and diarrhoea (15 [25%]). Median length of hospital stay was 2 days [IQR 1-3]). 122 (88%) of 138 children with available data needed standard ward care and 27 (20%) needed oxygen therapy. Seven (5%) of 138 children were ventilated and four (3%) died during the study period, all related to complex underlying copathologies. All children and 77 (92%) of 84 parents or guardians with available data were unvaccinated to COVID-19.
INTERPRETATION
Rapid increases in paediatric COVID-19 cases and hospitalisations mirror high community transmission of the SARS-CoV-2 omicron variant in Tshwane District, South Africa. Continued monitoring is needed to understand the long-term effect of the omicron variant on children and adolescents.
FUNDING
South African Medical Research Council, South African Department of Science & Innovation, G7 Global Health Fund.

Identifiants

pubmed: 35189083
pii: S2352-4642(22)00027-X
doi: 10.1016/S2352-4642(22)00027-X
pmc: PMC8856663
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

294-302

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

Nature. 2021 Dec;600(7887):21
pubmed: 34824381
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Acta Paediatr. 2020 Nov;109(11):2422
pubmed: 32521068
Lancet Respir Med. 2020 May;8(5):446-447
pubmed: 32224304
Pediatr Pulmonol. 2020 Aug;55(8):1892-1899
pubmed: 32492251
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
Pediatr Pulmonol. 2020 Oct;55(10):2565-2575
pubmed: 32725955
Paediatr Respir Rev. 2020 Sep;35:9-14
pubmed: 32593648
Int J Gen Med. 2020 Jul 28;13:477-482
pubmed: 32848446
Indian J Pediatr. 2020 Jun;87(6):433-442
pubmed: 32338347
Risk Manag Healthc Policy. 2020 Jun 25;13:661-669
pubmed: 32636686
Front Pediatr. 2021 Jan 20;8:614076
pubmed: 33553073
Pediatrics. 2020 Jul;146(1):
pubmed: 32376725

Auteurs

Jeané Cloete (J)

Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa; Centre for Maternal, Fetal, Newborn and Child Health Care Strategies, University of Pretoria, Pretoria, South Africa; Maternal and Infant Health Care Strategies Research Unit, South African Medical Research Council, Pretoria, South Africa. Electronic address: jeane.cloete@up.ac.za.

Annelet Kruger (A)

Centre for Maternal, Fetal, Newborn and Child Health Care Strategies, University of Pretoria, Pretoria, South Africa; Department of Family Medicine, University of Pretoria, Pretoria, South Africa; Maternal and Infant Health Care Strategies Research Unit, South African Medical Research Council, Pretoria, South Africa; Tshwane District Health Services, Gauteng Department of Health, Pretoria, South Africa.

Maureen Masha (M)

National Institute of Communicable Diseases, Johannesburg, South Africa; Right to Care, Johannesburg, South Africa.

Nicolette M du Plessis (NM)

Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa; Centre for Maternal, Fetal, Newborn and Child Health Care Strategies, University of Pretoria, Pretoria, South Africa; Maternal and Infant Health Care Strategies Research Unit, South African Medical Research Council, Pretoria, South Africa.

Dini Mawela (D)

Department of Paediatrics, Sefako Makgatho Health Sciences University, Dr George Mukhari Academic Hospital, Pretoria, South Africa.

Mphailele Tshukudu (M)

Tshwane District Health Services, Gauteng Department of Health, Pretoria, South Africa.

Tabea Manyane (T)

Tshwane District Health Services, Gauteng Department of Health, Pretoria, South Africa.

Lekwetji Komane (L)

Tshwane District Health Services, Gauteng Department of Health, Pretoria, South Africa.

Marietjie Venter (M)

Department of Medical Virology, University of Pretoria, Pretoria, South Africa.

Waasila Jassat (W)

National Institute of Communicable Diseases, Johannesburg, South Africa.

Ameena Goga (A)

Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa; HIV Prevention Research Unit, South African Medical Research Council, Pretoria, South Africa.

Ute Feucht (U)

Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa; Centre for Maternal, Fetal, Newborn and Child Health Care Strategies, University of Pretoria, Pretoria, South Africa; Maternal and Infant Health Care Strategies Research Unit, South African Medical Research Council, Pretoria, South Africa; Tshwane District Health Services, Gauteng Department of Health, Pretoria, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH